H-ITDQVPFSV-OH

Ref. 3D-PP42098

Product Information

• Name: H-ITDQVPFSV-OH

Description

Peptide H-ITDQVPFSV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ITDQVPFSV-OH include the following: Functional characterization of CTL against gp100 altered peptide ligands SO Dionne, MH Smith, FM Marincola - Cancer Immunology , 2003 - Springerhttps://link.springer.com/article/10.1007/s00262-002-0358-3 Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes SO Dionne, MH Smith, FM Marincola, DF Lake - Cellular immunology, 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0008874901918933 Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100209-2M peptide SL Meijer, A Dols, SM Jensen, HM Hu - Journal of , 2007 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2007/07000/Adoptive_Cellular_Therapy_With_Tumor_Vaccine.00008.aspx Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine OY Borbulevych , TK Baxter, Z Yu - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/8/4812/1745 An HLA-A2 polyepitope vaccine for melanoma immunotherapy L Mateo, J Gardner, Q Chen, C Schmidt - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/163/7/4058/105313 Recombinant Virus Vaccination against"Self" Antigens UsingAnchor-fixed Immunogens KR Irvine, MR Parkhurst, EP Shulman, JP Tupesis - Cancer research, 1999 - AACRhttps://aacrjournals.org/cancerres/article-abstract/59/11/2536/505166 Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation J Chapiro, S Claverol, F Piette, W Ma - The Journal of , 2006 - journals.aai.orghttps://journals.aai.org/jimmunol/article/176/2/1053/73604 Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination DJ Powell Jr, SA Rosenberg - Journal of immunotherapy, 2004 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2004/01000/Long_Term_Survival_of_Anti_Tumor_Lymphocytes.4.aspx Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines CL Slingluff , GR Petroni , ME Smolkin - Journal of , 2010 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2010/07000/immunogenicity_for_cd8__and_cd4__t_cells_of_2.8.aspx Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy A Nolte, C Scheffold, J Slotty, C Huenefeld - Journal of , 2003 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2003/05000/Response_Rates_of_Patients_With_Metastatic.9.aspx

• Brand: Biosynth